Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.
- The company has appointed Chilean drug policy specialist Felipe Leyton to lead commercialization in South America’s mining industry.
- The company is preparing to deploy its voice-based AI drug and alcohol impairment detection platform in industrial environments beginning in 2026, with Chile’s mining sector, employing more than 200,000 workers, representing an early target market.
- MindBio’s technology analyzes voice patterns to detect intoxication or impairment without biological testing, and management is positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries.
- The company also recently closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, is moving toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector.
The biotechnology company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from technology development to field implementation in large enterprise environments (https://ibn.fm/pOUPF).
Leyton brings experience in national drug policy and workplace safety, having helped design and implement Chile’s “Zero Tolerance” alcohol-impaired driving law as part of the country’s alcohol prevention framework. He also played a role in establishing Chile’s roadside drug testing program introduced in 2019. His appointment reflects MindBio’s strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
Leyton currently advises major mining operators and government agencies through consulting firm TConsulting, where he focuses on prevention strategies, regulatory compliance and occupational health programs. Under his engagement with MindBio, he will oversee the development of testing protocols tailored for mining operations and coordinate early deployment of the company’s technology in active industrial environments.
MindBio’s platform uses acoustic biomarker analysis to detect signs of intoxication through voice patterns. The system evaluates more than 140 parameters extracted from speech and processes those signals through machine learning models trained on tens of millions of data points. The result is a prediction model designed to estimate alcohol impairment and identify potential drug intoxication in real time without the need for blood, urine or breath samples.
The company is preparing to integrate this technology into a dedicated Edge AI hardware platform intended for deployment at worksites. The system will operate through voice-initiated kiosk terminals that can perform rapid screening of workers entering industrial facilities.
According to MindBio, prototype development of the kiosk-based hardware system is nearing completion, with field testing expected to begin during the second quarter of 2026. The platform is designed to deliver rapid screening results on site while reducing operational delays often associated with conventional biological testing.
Industrial safety is a significant concern in mining operations, particularly in regions where large workforces operate heavy machinery in remote environments. Data cited by MindBio suggests that alcohol consumption among mining workers in Chile exceeds 75%, with roughly 40% categorized as problem drinkers and approximately 9% reporting drug use. These figures point to a broader challenge faced by industrial employers seeking to reduce workplace accidents linked to impairment. Global research has estimated that between 20% and 25% of occupational accidents are directly or indirectly associated with substance use.
In this context, technologies capable of rapidly screening large numbers of workers could have operational and regulatory relevance for companies managing high-risk industrial sites. MindBio’s enterprise strategy centers on providing scalable screening systems that can be deployed at entry points to industrial facilities. The company believes voice analysis can reduce the friction associated with traditional testing methods, which often require biological samples and specialized laboratory processing. By contrast, voice analysis requires only a short spoken input, allowing results to be generated in seconds.
The company’s technology is supported by a large clinical dataset generated through several years of research. According to MindBio, the AI prediction model has been trained on more than 50 million data points derived from speech analysis and controlled studies measuring alcohol intoxication levels. Early testing has demonstrated accuracy rates exceeding 85% for blood alcohol concentration prediction and roughly 88% for intoxication classification.
Beyond mining, MindBio is developing applications for aviation, construction and other safety-critical industries where impairment detection is required by regulatory frameworks or company policy.
The company also operates a consumer-facing product called Booze AI, which enables individuals to estimate their blood alcohol concentration using voice input through a smartphone or web interface. This dual strategy, consumer applications alongside enterprise deployment, provides multiple potential commercialization pathways.
To support these initiatives, MindBio recently expanded a previously announced financing round (https://ibn.fm/GKqOk). The company recently closed a non-brokered private placement that had been upsized from $650,000 to up to $1.5 million. The offering consisted of units priced at $0.60, each including one common share and one warrant exercisable at $0.80 for up to 36 months following closing. Proceeds are expected to support engineering development, field deployment activities and commercialization initiatives, including expansion into South American mining operations.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
